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Abstract
Background: Osteoporosis is characterized by low bone mass and compromised bone structure, heritable traits that
contribute to fracture risk. There have been no genome-wide association and linkage studies for these traits using high-
density genotyping platforms.
Methods: We used the Affymetrix 100K SNP GeneChip marker set in the Framingham Heart Study (FHS) to examine
genetic associations with ten primary quantitative traits: bone mineral density (BMD), calcaneal ultrasound, and
geometric indices of the hip. To test associations with multivariable-adjusted residual trait values, we used additive
generalized estimating equation (GEE) and family-based association tests (FBAT) models within each sex as well as sexes
combined. We evaluated 70,987 autosomal SNPs with genotypic call rates ≥80%, HWE p ≥ 0.001, and MAF ≥10% in up
to 1141 phenotyped individuals (495 men and 646 women, mean age 62.5 yrs). Variance component linkage analysis was
performed using 11,200 markers.
Results: Heritability estimates for all bone phenotypes were 30–66%. LOD scores ≥3.0 were found on chromosomes
15 (1.5 LOD confidence interval: 51,336,679–58,934,236 bp) and 22 (35,890,398–48,603,847 bp) for femoral shaft
section modulus. The ten primary phenotypes had 12 associations with 100K SNPs in GEE models at p < 0.000001 and
2 associations in FBAT models at p < 0.000001. The 25 most significant p-values for GEE and FBAT were all less than 3.5
× 10-6 and 2.5 × 10-5, respectively. Of the 40 top SNPs with the greatest numbers of significantly associated BMD traits
(including femoral neck, trochanter, and lumbar spine), one half to two-thirds were in or near genes that have not
previously been studied for osteoporosis. Notably, pleiotropic associations between BMD and bone geometric traits
were uncommon. Evidence for association (FBAT or GEE p < 0.05) was observed for several SNPs in candidate genes
for osteoporosis, such as rs1801133 in MTHFR; rs1884052 and rs3778099 in ESR1; rs4988300 in LRP5; rs2189480 in VDR;
rs2075555 in COLIA1; rs10519297 and rs2008691 in CYP19, as well as SNPs in PPARG (rs10510418 and rs2938392) and
ANKH (rs2454873 and rs379016). All GEE, FBAT and linkage results are provided as an open-access results resource at
http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007.
Conclusion: The FHS 100K SNP project offers an unbiased genome-wide strategy to identify new candidate loci and to
replicate previously suggested candidate genes for osteoporosis.
Published: 19 September 2007
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Introduction
Osteoporosis is a skeletal disorder characterized by com-
promised bone strength leading to an increased risk of
fracture [1]. In the United States alone, there are over 1.5
million fractures each year, including 280,000 hip frac-
tures and 500,000 vertebral fractures. According to the
recent U.S. Surgeon General's Report on Skeletal Health,
fractures remain a large and growing public health con-
cern [2]. Presently, the gold standard for assessment of
fracture risk is measurement of bone mineral density
(BMD, g/cm2) by dual-energy X-ray absorptiometry
(DXA). Whereas low BMD is among the strongest risk fac-
tors for fracture [3,4], a number of clinical studies have
demonstrated that other measurements, such as quantita-
tive ultrasound (QUS) and bone geometry, are important
for fracture prediction and osteoporosis treatment moni-
toring [5-7]. Thus, QUS of the calcaneus is associated with
hip fracture, largely independent of BMD [8,9]. A growing
body of evidence in recent years indicates that femoral
geometry also contributes importantly to hip fracture risk
[10,11].
BMD, QUS, and femoral bone geometry are approxi-
mately normally distributed, complex traits. A wealth of
studies have documented BMD to be under strong genetic
control with 50–70% heritability [12,13]. Similarly, QUS
[8,14,15] and hip geometry [16-19] are probably regu-
lated by additive genetic factors. However, despite years of
research in the field of osteoporosis genetics, progress to
date has been modest in successfully identifying major
genes determining BMD, QUS, and bone geometry in the
general population. The numbers of quantitative trait loci
(QTLs) and genes linked and/or associated with oste-
oporosis-related phenotypes continue to expand and the
list has become considerably more detailed and complex.
More than 20 genome linkage scans to date have revealed
multiple QTLs covering all chromosomes but the Y chro-
mosome [20]. Moreover, the results from one study have
inconsistently been replicated in other samples. To over-
come these obstacles, a collaborative meta-analysis of 9
genome-wide linkage searches of BMD was recently con-
ducted, including data from 11,842 subjects, members of
3,045 families [13]. The meta-analysis suggested a
number of specific QTLs to be pursued further (1p13.3-
q23.3 and 1q32-q42.3, 3p25.3-p22.1, 11p12-q13.3,
12q24.31-qter, and 18p11-q12.3). An additional factor
that adds to the complexity of finding genes for oste-
oporosis-related traits is the notion (including our own
[21,22]) that QTLs for bone density and geometry [23] are
skeletal site-specific, age-group-, and sex-specific [24,25].
Numerous biological candidate genes for bone pheno-
types have also been proposed, but few have been vali-
dated with large-scale evidence [13]. Recent meta-analyses
for estrogen receptor alpha [26], collagen type I alpha 1
[27], methylenetetrahydrofolate reductase, [28] and vita-
min D receptor [29] genes demonstrated that the poly-
morphisms in these genes each explain a small percentage
of the variation in BMD or fracture. With the near comple-
tion of the International HapMap Project and the rapid
improvements in high throughput genotyping technol-
ogy, the ultimate understanding of the genetic basis of
osteoporosis may come from a genome-wide association
approach in which the whole human genome is surveyed
for common genetic variation in osteoporosis-related her-
itable quantitative traits such as BMD [19]. To further
advance the field of skeletal genetics, efforts are now turn-
ing toward studies that are able to cover the vast majority
of the genome with a dense set of SNPs, in order to iden-
tify the genes linked and/or associated with osteoporosis-
related traits. We thus performed genome-wide linkage
and association analyses using a dense genome scan in
members of extended pedigrees from the Framingham
Heart Study (FHS).
Materials and methods
Study sample
The Framingham Osteoporosis Study is an ancillary study
of the Framingham Heart Study (see description of the
FHS sample in the Overview paper [30]). Beginning at
biennial examination 20 of the Original Cohort, bone
mineral density (BMD) was obtained using single and
dual photon absorptiometry. The Original Cohort partic-
ipants underwent bone densitometry by DXA with a
Lunar DPX-L (Lunar Corp., Madison, WI, USA) during
their examination 22 (1992–1993). In order to maximize
the sample size, we used DXA scans from examination 24
(in 1996–1997) for 31 Original Cohort members who did
not have DXAs at examination 22. The Offspring Cohort
was scanned with the same machine at their examination
cycle 6 or 7 (between 1996 and 2001). Right calcaneal
bone ultrasonography (QUS) was performed with a port-
able QUS device, the Sahara® bone sonometer (Hologic,
Inc., Waltham, MA), in members of the Offspring Cohort
at their examination cycle 6/7 and the Original Cohort
during their exam 24 assessment. There were 1141 pheno-
typed individuals, 245 from the Original Cohort (86 men
and 159 women, mean age 77.5 yrs) and 896 Offspring
Cohort participants (409 men and 487 women, mean age
58.5 yrs), belonging to 241 families.
Phenotype definition and residual creation
Original Cohort participants had bone measures per-
formed at either exam 22 or 24. Offspring Cohort partici-
pants had these measures obtained during a period that
included part of the official Framingham exams 6 and 7.
The following traits were studied: Bone mineral density
(including femoral neck, FNBMD; trochanter, TRBMD;
L2–L4 lumbar spine, LSBMD); quantitative ultrasound of
the calcaneus (broadband ultrasound attenuation, BUA;BMC Medical Genetics 2007, 8(Suppl 1):S14 http://www.biomedcentral.com/1471-2350/8/S1/S14
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speed of sound, SOS), and geometric indices of the hip
from DXA (femoral neck-shaft angle, NSA; femoral neck
length, NeckLeng; section modulus, Z, and width, W, at
the "narrow neck", Neck, and the shaft, S, regions of the
hip). In total, 10 traits are reported here. Details of the
measurements and phenotype definition [15,23,31] as
well as coefficients of variation for the different compo-
nent variables were previously reported for BUA (5.3%),
SOS (0.4%) [32], LSBMD (0.9%), FNBMD (1.7%),
TRBMD (2.5%) [33], and for the geometric traits, ranged
from 3.3% (NeckW) to 9.1% (NeckLeng) [34].
Multivariate regression analysis was performed in each sex
(men and women) and Cohort (Original and Offspring)
in order to obtain normalized or ranked residual pheno-
types, adjusted for covariates. Table 1 lists the covariates
used for each trait. The covariate measurements have been
described in previous work [22]. We used ranked residuals
in order to correct for the deviations from the normal kur-
tosis and skewness in some of the phenotypes, since vari-
ance component analysis (VCA) is sensitive to the high
kurtosis [35]. 
Genotyping methods
We used the Affymetrix 100K SNP GeneChip marker set in
the Framingham Heart Study to examine genetic associa-
tions with the above phenotypes (see description of the
FHS 100K and Marshfield STRs in the Overview  paper
[30]). We evaluated autosomal SNPs with genotypic call
rates ≥80%, HWE p ≥ 0.001, MAF ≥10% in up to 1141
phenotyped individuals (495 men and 646 women). Ulti-
mately, 70,987 SNPs were analyzed.
Statistical analysis methods
We performed genome-wide association (GWA) analyses
by two approaches, using both family-based and popula-
tion-based methods. (See description of the general statis-
tical methods for GWA and linkage analyses in the
Overview paper [30]). Both sex-specific and combined-
sexes analyses were performed. We used additive general-
ized estimating equation (GEE) and family-based associa-
tion tests (FBAT) models to test associations of our
phenotypes. Family based association testing has a great
power to detect genetic variants of modest effect size
[30,36].
In order to prioritize SNPs potentially associated with
multiple phenotypes, we evaluated several phenotypic
subgroups: (1) clinically important bone mineral density
traits (FNBMD, TRBMD, LSBMD), (2) a combination of
BMDs with BUA, (3) hip geometry (NSA, NeckLeng,
NeckW and ShaftW), and (4) hip BMDs with hip geome-
try. We also focused on BMD in sex-specific subgroups.
For each SNP we calculated the number of traits signifi-
cantly associated with this SNP at alpha <0.01 in both
GEE and FBAT, assuring that the FBAT and GEE effects
were in the same direction. We then selected top SNPs
with highest numbers of nominally significantly associ-
ated traits. For identical proportions of nominally signifi-
cant traits, SNPs were additionally ranked by the mean of
GEE p-values across traits (as well, GEE p-values were used
for SNP ranking in the sex-specific subgroups due to a
small sample size for FBAT analysis).
For SNPs that were selected by more than one strategy and
that pertained to a specific gene (according to the NCBI
Build 35), we perused Entrez  Gene and also queried
PubMed using the gene name and "osteoporosis", "frac-
ture" or "bone mass" terms, in order to identify biological
plausibility or evidence relating these genes specifically to
bone disease.
Variance component analyses (VCA) for all phenotypes
were performed on normalized or rank-normalized resid-
uals using the computer package Sequential Oligogenic
Linkage Analysis Routines (SOLAR, SFBR/NIH, San Anto-
nio, TX) version 2.0, available online http://
www.sfbr.org/solar/doc/00.contents.html. Heritability
(h2) of each phenotype was estimated as the proportion of
the total phenotypic variance attributable to the additive
effects of genes. Subsequent linkage analyses were also
conducted using SOLAR. This method, described in detail
elsewhere [37] (see description of the linkage methods in
the Overview paper [30]), entails specification of the
genetic covariance between arbitrary relatives as a func-
tion of the identity-by-descent (IBD) relationships at a
given marker locus and models the covariance matrix for
a pedigree as the sum of the additive genetic covariance
attributable to the QTL, the additive genetic covariance
due to the effects of loci other than the QTL, and the vari-
ance due to unmeasured environmental factors. VCA link-
age used IBDs values that were calculated from 11,200
markers.
Results
Bone-related quantitative traits and derived phenotypes
analyzed in the FHS 100K SNP resource are listed in Table
1. Each trait was analyzed as multivariable-adjusted resid-
uals from cohort- and sex-specific models; in addition,
geometric traits were adjusted for age, age2 only. Among
these, the following ten multivariable-adjusted residuals
are the primary phenotypes presented here: BMD of the
femoral neck (FNBMD; n with data = 1141), trochanter
(TRBMD; n = 1141) and the second to fourth vertebral
bodies of the lumbar spine (LSBMD; n = 1127); a quanti-
tative ultrasound measure of the calcaneus, broadband
ultrasound attenuation (BUA; n = 1105); femoral geome-
try measures at the "narrow neck" region of the hip and
the femoral shaft including narrow neck section modulus
(NeckZr; n = 1107) and width (NeckWr; n = 1106), fem-BMC Medical Genetics 2007, 8(Suppl 1):S14 http://www.biomedcentral.com/1471-2350/8/S1/S14
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oral shaft section modulus (ShaftZr; n = 1037) and width
(ShaftW; n = 1037), femoral neck-shaft angle (NSA; n =
1107), and femoral neck length (NeckLeng; n = 1101).
Additional bone-related quantitative phenotypes are
available in the FHS 100K SNP resource (web posted at
http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?id=phs000007) including calcaneal speed of
sound; several hip geometry measures including neck
cross-sectional moment of inertia; neck, shaft and inter-
trochanteric buckling ratio, and shaft cross sectional
moment of inertia from these same examinations.
Heritability estimates for all bone phenotypes ranged
from 30–66%. We consider here only multivariable-
adjusted, residual phenotypes derived from ten primary
traits defined above. There were 12 associations with
100K SNPs in GEE models at p < 0.000001 and 2 associa-
tions in FBAT models with p < 0.000001. The 25 SNPs
Table 1: Phenotypes included in the study
Trait Abbreviation Gender (N) Cohort, exam cycle Adjustment*
Bone mineral density (BMD)
Femoral BMD** FNBMD Combined (1141) Original, ex. 22–24, Offspring, 
ex. 6–7
1) multivariable-adjusted residuals (age, age2, height, 
BMI, smoking, physical activity, estrogen therapy)
FNBMDf Females (646)
FNBMDm Males (495)
Trochanter BMD** TRBMD Same as above Same as above Same as above
TRBMDf
TRBMDm
Lumbar spine BMD** LSBMD Combined (1117) Same as above Same as above
LSBMDf Females (641)
LSBMDm Males (486)
Quantitative ultrasound (QUS)
Broadband ultrasound attenuation** BUA Combined (1105) Original, ex. 24, Offspring, ex. 
6–7
1) multivariable-adjusted residuals (age, age2, height, 
BMI, smoking, physical activity, estrogen therapy)
Speed of Sound SOS Combined (1104) Same as above Same as above
Hip geometry
Neck-shaft angle** NSA1 Combined (1096) Original, ex. 22–24, Offspring, 
ex. 6–7
1) age, age2
2) multivariable-adjusted ranked residuals (age, age2, 
height, BMI)
NSAf Females (622)
NSAm Males (474)
Femoral neck length** NeckLeng1 Combined (1090) Same as above Same as above
NeckLengf Females (619)
NeckLengm Males (471)
Neck width** NeckW1r Combined (1095) Same as above Same as above
NeckW1rf Females (618)
NeckW1rm Males (477)
Neck section modulus** NeckZ1r Combined (1096) Same as above Same as above
NeckZ1rf Females (618)
NeckZ1rm Males (478)
Neck Cross-Sectional Moment of Inertia NeckCSMI1r Combined (1094) Same as above Same as above
NeckCSMI1rf Females (618)
NeckCSMI1rm Males (476)
Neck Average Buckling Ratio NeckAvgBR1r Combined (1096) Same as above Same as above
NeckAvgBR1rf Females (618)
NeckAvgBR1rm Males (478)
Shaft width** ShaftW1 Combined (1028) Same as above Same as above
ShaftW1f Females (599)
ShaftW1m Males (429)
Shaft Section modulus** ShaftZ1r Combined (1028) Same as above Same as above
ShaftZ1rf Females (599)
ShaftZ1rm Males (429)
Shaft Cross-Sectional Moment of Inertia ShaftCSMIr Combined (1026) Same as above Same as above
ShaftCSMIrf Females (599)
ShaftCSMIrm Males (427)
Shaft Average Buckling Ratio ShaftAvgBR1r Combined (1028) Same as above Same as above
ShaftAvgBR1rf Females (599)
ShaftAvgBR1rm Males (429)
Inter-Trochanteric Average Buckling Ratio ITAvgBR1r Combined (1024) Same as above Same as above
ITAvgBR1rf Females (596)
ITAvgBR1rm Males (428)
*adjustment performed in each Cohort (generation) and gender
**primary traits reported hereBMC Medical Genetics 2007, 8(Suppl 1):S14 http://www.biomedcentral.com/1471-2350/8/S1/S14
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with the lowest p-values in GEE (p < 3.5 × 10-6) and FBAT
models (p < 2.5 × 10-5), ordered by chromosomal posi-
tion, are shown in Tables 2a and 2b, respectively. Of these
SNPs, 10 (GEE) and 19 (FBAT) were within 60 kb of a
known gene. Several SNPs associated with phenotypes
were in high pairwise LD (r2 ≥ 0.8). When this occurred we
displayed results for the higher ranking SNP based on a
combination of FBAT and GEE p-values. Of note, some
SNPs were associated with more than one trait: thus,
rs10514345 on chromosome 5 was associated (GEE) with
NeckZ1 (combined sample) and LSBMD (females) and
rs1209921 on chromosome 21 was associated (FBAT)
with TRBMD (combined sample) and FNBMD (females)
(Tables 2a and 2b, respectively).
In Table 2c we present results with LOD scores above 2.0
from genome-wide linkage analyses with their corre-
sponding 1.5-LOD confidence interval. There were link-
age peaks observed for the majority of chromosomes, and
in general there were a greater number of linkages with
bone geometry traits than with either BMD or ultrasound
measures. LOD scores ≥3.0 were found on chromosomes
15 (1.5 LOD support interval, 51,336,679–58,934,236
bp) and 22 (35,890,398–48,603,847 bp), with femoral
shaft section modulus. There were no linkage regions of
overlap with markers that were found to be associated
with bone phenotypes in the FBAT and GEE analyses.
Notably, when we restricted our sample to members of
the Offspring Cohort, LOD scores for BMD phenotypes
increased; for example, for LSBMD on chr. 7 (63,211,216
bp) from 1.25 to 2.43; for FNBMD on chr. 9 (104,660,212
bp) from 1.79 to 2.65, and on chr. 17 (63,038,023 bp)
from 1.83 to 2.43 (not shown in the Table 2c).
In order to prioritize SNPs potentially associated with
multiple phenotypes, we evaluated four phenotypic sub-
groups by both population- and family-based tests. The
first subgroup was BMD (femoral neck, trochanter and
spine), the second was BMD + bone ultrasound (BUA),
the third was bone geometry (femoral neck-shaft angle,
femoral neck length, femoral neck width, and shaft
width), and the fourth, hip BMDs with hip geometry. For
each SNP we calculated the number of traits in the sub-
group that were significantly associated with the SNP at p
< 0.01 in both GEE and FBAT, and then ranked SNPs with
highest numbers of nominally significantly associated
traits in which the direction of association was the same.
In cases where SNPs had the same proportions of nomi-
nally significant traits, SNPs were additionally ranked by
the mean of GEE p-values across traits.
In Table 3a we present only the SNPs selected based on
associations with p-value of both GEE and FBAT < 0.01
with the first subgroup (BMD phenotypes only), for a
combined sample of men and women. Using the annota-
tion by UCSC genome browser tables http://
genome.ucsc.edu/, of the top 20 SNPs for the BMD sub-
group, 9 (45%) were identified in genes or within 60 kb
of a known gene, and none were coding (Table 3a). The
nominally significant intragenic SNPs were found in sev-
eral genes, including cadherin 9 type 2 (CDH9) on 5p14
and gene deleted in colorectal carcinoma (DCC) on
18q21. It is also noteworthy that the association of
TRBMD with rs1209926 on chr. 21 (39,078,994 bp)
occurred in the region identified in our original genome-
wide linkage study in the FHS [22] SNP rs2938392 in the
peroxisome proliferator-activated receptor gamma
(PPARG) was also associated with the BMD traits in GEE
tests and less strongly in FBAT analyses (not shown in
Table 3a).
We also examined men and women separately within the
first phenotypic subgroup and confirmed the associations
of BMD phenotypes, observed in the combined sample,
with rs922028 (chromosome 4, no known gene),
rs1479679 (in CDH9, chr. 5), and rs768207 (in DCC, chr.
18), all in women (Table 3b). There were also associations
in one sex that were neither observed in the other sex nor
in the combined sample, and men and women did not
share many polymorphisms associated with BMD.
We also looked for evidence of pleiotropy by evaluating
association results within the other three pre-specified
phenotype subgroups, BMD + BUA and hip geometry, as
well as combinations of hip BMD with hip geometry
(fourth subgroup). Notably, pleiotropic associations
between BMD and other traits were uncommon (not
shown in a table). When considering BMD and BUA
together (phenotype subgroup 2), there were nominally
significant associations (p < 0.0005) with a SNP rs953934
in the interleukin 1 receptor-like 1 gene (IL1RL1) on 2q12
(not shown). Of the top SNPs for the Hip Geometry sub-
group (NSA, NeckLeng, NeckW1r and ShaftW1), 50%
were identified in genes or within 60 kb of a known gene;
none were coding. The nominally significant intragenic
SNPs were found in several genes, including rs7151976 in
heat shock 70 kD protein 2 (HSPA2) on 14q24 and
rs2834719 in runt-related transcription factor 1 (RUNX1,
or  CBFA2) on 21q22. Significant associations of SNPs
with BMD phenotypes did not overlap with geometric
phenotypes, and within the hip geometry subgroup, SNPs
significant for one geometric phenotype did not overlap
with other phenotypes within this subgroup (data not
shown).
We further queried the FHS 100K array results, to verify, in
silico, whether previously reported candidate genes for
osteoporosis were associated with BMD, QUS and bone
geometry in our sample. Thus Table 4 shows SNPs in these
pre-defined candidate genes that were associated at p ≤BMC Medical Genetics 2007, 8(Suppl 1):S14 http://www.biomedcentral.com/1471-2350/8/S1/S14
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Table 2: Top genetic associations with bone density and geometry based on the lowest p-value for GEE test (2a), FBAT (2b), and 
Linkage (2c) analyses
2a: Top 25 associations with bone density and geometry based on the lowest p-value of the GEE test
Phenotype SNP Chrom. Physical  Position GEE p-value FBAT p-value Gene region*
NeckZ1rf rs6600671 1 120,812,532 5.85 × 10-7 3.18 × 10-3
NeckZ1 rs2053506 3 19,350,795 3.74 × 10-6 2.68 × 10-2 KCNH8
TRBMDm rs10510628 3 29,828,407 2.83 × 10-6 2.91 × 10-2 RBMS3
NeckW1rf rs2054989 3 56,505,749 6.06 × 10-7 2.36 × 10-3 ERC2
ShaftW1f rs922948 3 69,525,327 1.75 × 10-6 3.47 × 10-3
ShaftW1 rs991258 3 103,256,733 5.32 × 10-7 3.12 × 10-2
BUA rs9291683 4 10,000,429 2.07 × 10-6 7.44 × 10-4
NeckZ1rf rs2548003 5 28,783,080 2.40 × 10-7 1.30 × 10-1
NeckZ1rf rs10515148 5 71,752,684 6.10 × 10-7 5.97 × 10-3 ZNF366
LSBMDf rs10514345 5 90,460,035 2.15 × 10-6 9.85 × 10-2 GPR98
NeckZ1 Same as above 1.81 × 10-7 3.03 × 10-2
NeckW1rf rs4715166 6 13,324,037 2.69 × 10-6 9.97 × 10-3 PHACTR1
BUA rs2214681 7 147,140,340 2.72 × 10-6 2.26 × 10-2 CNTNAP2
ShaftZ1R rs10503887 8 31,752,989 2.23 × 10-7 1.77 × 10-3 NRG1
FNBMDm rs2165468 10 3,506,105 1.07 × 10-6 6.71 × 10-2
ShaftW1f rs1452928 11 84,499,969 7.10 × 10-7 7.43 × 10-3
NeckZ1rf rs638882 11 115,269,255 3.50 × 10-6 6.33 × 10-3
ShaftZ1rf rs10492096 12 6,450,843 3.35 × 10-6 2.17 × 10-3 VAMP1
TRBMD rs10506701 12 72,872,477 1.40 × 10-6 1.25 × 10-1
ShaftW1f rs10506821 12 78,999,391 2.03 × 10-7 1.80 × 10-1
NeckZ1rm rs1590305 13 36,933,189 3.15 × 10-6 2.21 × 10-2
FNBMDm rs9317284 13 62,532,351 2.44 × 10-7 2.86 × 10-1
TRBMDf rs4087296 16 80,935,282 3.11 × 10-7 6.18 × 10-3
NSAm rs4131805 18 24,313,110 2.07 × 10-6 1.87 × 10-3
TRBMDf rs4811196 20 35,903,108 1.13 × 10-6 7.03 × 10-4 CTNNBL1
2b: Top 25 associations with bone density and geometry based on the lowest p value of the FBAT test
Phenotype SNP Chrom. Physical Position GEE p-value FBAT p-value Gene region
NeckW1rf rs1395548 1 162,045,085 2.34 × 10-3 1.22 × 10-6 LMX1A
FNBMD rs1538173 1 165,373,720 6.77 × 10-2 2.80 × 10-6 DPT
TRBMD rs3762397 1 196,821,876 5.96 × 10-3 2.78 × 10-7 NR5A2
ShaftZ1rf rs9287234 1 236,892,414 9.71\ × 10-3 7.90 × 10-6 FMN2
TRBMD rs914951 1 239,278,119 1.82 × 10-2 8.79 × 10-6
NeckW1 rs4143244 3 5,385,364 1.07 × 10-2 7.05 × 10-7
NeckW1rf rs1349205 3 54,093,157 2.22 × 10-2 1.42 × 10-5 CACNA2D3
ShaftW1 rs1870007 3 109,458,022 1.71 × 10-1 1.32 × 10-5 IFT57/HHLA2
FNBMDf rs950649 3 121,567,065 7.63 × 10-4 2.00 × 10-5 FSTL1BMC Medical Genetics 2007, 8(Suppl 1):S14 http://www.biomedcentral.com/1471-2350/8/S1/S14
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NSA1 rs432446 4 127,906,277 2.84 × 10-2 5.19 × 10-6
FNBMD rs922028 4 181,162,903 9.55 × 10-3 1.53 × 10-5
FNBMD rs1823926 5 119,882,620 2.62 × 10-1 1.27 × 10-5 PRR16
NSA1 rs10503733 8 23,589,963 4.29 × 10-4 1.79 × 10-5 NKX3-1
NSAm rs10503953 8 33,917,325 1.86 × 10-3 1.32 × 10-5
NSAf rs4876377 8 118,556,170 4.56 × 10-2 1.93 × 10-5 THRAP6
NSAf rs10505600 8 133,882,045 2.48 × 10-1 1.36 × 10-5 PHF20L1
NSA1 rs1552896 9 14,831,387 4.02 × 10-1 8.87 × 10-6 FREM1
NeckZ1rm rs7857590 9 18,979,893 1.36 × 10-1 8.08 × 10-6 C9orf138
BUA rs700760 9 86,164,178 3.82 × 10-2 1.42 × 10-5 ZCCHC6
FNBMDf rs2378731 9 87,175,111 5.53 × 10-4 1.21 × 10-5
LSBMDm rs10512315 9 103,334,877 1.70 × 10-1 2.28 × 10-5
NeckW1rf rs2048741 9 117,716,816 5.49 × 10-3 2.40 × 10-5
ShaftZ1rm rs6744 9 124,988,623 9.58 × 10-2 1.05 × 10-5 C9orf126
NeckLengf rs773985 10 34,822,758 3.18 × 10-2 1.05 × 10-5 PARD3
NeckLengf rs10490924 10 124,204,438 1.11 × 10-1 1.80 × 10-5 PLEKHA1/HTRA1
FNBMDm rs10508076 13 101,270,253 5.41 × 10-3 4.35 × 10-6 FGF14
TRBMD rs1865968 16 57,535,751 1.15 × 10-1 1.72 × 10-5
TRBMD rs1209921 21 39,078,145 2.51 × 10-4 2.41 × 10-5 C21orf24/ETS2
FNBMDf Same as above 5.32 × 10-5 6.65 × 10-3
2c. Magnitude and Location of Peak LOD scores >2.5 for regions in the bone density and geometry phenotype group
Phenotype marker Chrom. physical location maxLOD 1.5 LOD confidence 
interval
NeckLeng1 rs1759687 1 112,663,861 2.80 102,547,964–
119,889,867
ShaftW1 rs2320625 2 95,284,610 2.85 85,198,107–
105,339,005
NSA1 rs1304771 2 123,061,290 2.80 108,949,962–
129,987,436
BUA rs842288 3 16,291,319 2.08 8,499,321–40,075,261
NeckZ1 rs1386389 4 112,310,874 2.33 102,722,423–
131,391,829
NeckW1 rs2094541 10 130,314,425 2.56 128,465,158–
135,165,518
LSBMD rs10492028 12 111,799,883 2.10 103,438,302–
117,318,152
ShaftZ1 rs10518923 15 55,573,538 3.02 51,336,679–58,934,236
NeckW1 AFM049xd2 16 22,945,152 2.34 16,856,153–24,665,428
BUA rs10492922 16 27,519,162 2.20 26,434,120–50,596,704
NeckZ1 rs6502901 17 5,864,832 2.37 451,209–8,829,083
BUA rs8081154 17 46,196,038 2.12 37,926,265–62,642,504
NeckW1 rs750160 20 649,631 2.10 161,523–4,335,440
ShaftZ1 rs7290139 22 44,039,280 3.01 35,890,398–48,603,847
* SNP in a gene(s) or near (within 60 kb)
Table 2: Top genetic associations with bone density and geometry based on the lowest p-value for GEE test (2a), FBAT (2b), and 
Linkage (2c) analyses (Continued)BMC Medical Genetics 2007, 8(Suppl 1):S14 http://www.biomedcentral.com/1471-2350/8/S1/S14
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0.05 in either GEE or FBAT models. We selected the fol-
lowing six previously reported genes that had been exten-
sively studied: COL1A1, CYP19, ESR1, LRP5, MTHFR, and
VDR. For the MTHFR gene, we found 1 non-synonymous
coding SNP (rs1801133) that was associated with femoral
shaft section modulus and neck-shaft angle by GEE and
FBAT, respectively. We [38] have previously reported an
association of this SNP with BMD in unrelated partici-
pants in the Framingham Osteoporosis Study and others
have confirmed this association [28,39]. None of the
three 100K SNPs in the ESR1 gene (rs1884052, rs3778099
and rs3866461) with nominally significant associations
with bone phenotypes were in LD with widely published
SNPs (rs2234693 and rs9340799). A single intronic 100K
SNP from LRP5 (rs4988300) was associated with shaft
section modulus in males and with femoral neck BMD in
females. This 100K SNP was not in LD with published
rs3736228 in LRP5 [40]. There were no LD data available
Table 3: Combination of FBAT and GEE, for grouped BMD phenotypes*
3a: Combination of FBAT and GEE, for grouped BMD phenotypes in men and women combined
Chrom Physical Position SNP Min p-value by 
GEE
Min p-value by 
FBAT
% Significant P-values by 
GEE & FBAT**
Function Gene symbol
1 177,489,285 rs7544774 3.34 × 10-4 7.55 × 10-3 67 intron XPR1
1 231,181,475 rs7554650 1.67 × 10-4 5.93 × 10-3 67 unknown
2 6,719,916 rs7584788 7.55 × 10-3 5.19 × 10-4 67 unknown
2 15,963,228 rs2380707 1.14 × 10-3 5.22 × 10-4 67 unknown
2 79,078,098 rs1261226 1.19 × 10-5 4.47 × 10-3 67 unknown
4 177,742,191 rs9312601 2.22 × 10-3 7.03 × 10-4 67 unknown
4 181,139,118 rs10520437 5.23 × 10-4 7.72 × 10-5 100 unknown
4 181,162,903 rs922028 8.45 × 10-4 1.53 × 10-5 100 unknown
5 26,917,842 rs1479679 1.13 × 10-4 2.38 × 10-4 67 intron CDH9
5 53,527,854 rs16882423 1.65 × 10-3 2.38 × 10-3 67 intron ARL15
7 9,739,152 rs1557978 1.73 × 10-4 3.97 × 10-4 33 intron
7 11,301,740 rs10486135 1.67 × 10-4 5.95 × 10-4 67 intron
7 18,183,021 rs10486301 1.94 × 10-4 9.43 × 10-4 67 unknown
8 114,092,330 rs1156075 5.55 × 10-3 8.51 × 10-3 67 intron CSMD3
11 95,219,586 rs546809 1.41 × 10-3 7.10 × 10-5 67 intron MTMR2
12 103,526,872 rs10507180 7.18 × 10-4 4.16 × 10-3 100 intron CHST11
16 76,268,225 rs8051539 2.08 × 10-3 5.80 × 10-3 67 unknown
18 48,132,968 rs768207 1.94 × 10-3 2.99 × 10-3 67 intron DCC
19 42,607,072 rs1465434 1.51 × 10-3 7.17 × 10-4 67 intron ZNF569
21 39,078,994 rs1209926 2.51 × 10-4 3.21 × 10-5 33 unknown C21orf24/ETS2
3b: Sex-specific results for grouped BMD phenotypes†
Chrom Physical Position SNP Sex Min p-value by 
GEE‡
Min p-value by FBAT‡ Function Gene symbol
1 48,261,693 rs560004 Males 8.91 × 10-4 3.48 × 10-3 unknown
1 200,641,877 rs1935588 Females 6.14 × 10-4 7.62 × 10-4 unknown
2 125,809,045 rs1215318 Males 1.23 × 10-4 2.96 × 10-4 unknown
4 181,162,903 rs922028 Females 1.61 × 10-4 6.16 × 10-3 unknown
5 26,917,842 rs1479679 Females 4.36 × 10-5 6.96 × 10-3 intron CDH9
6 47,657,085 rs9296566 Females 2.27 × 10-4 5.08 × 10-4 intron CD2AP
6 83,666,784 rs9294266 Males 5.32 × 10-4 2.01 × 10-3 intron C6orf157
7 33,440,554 rs10486541 Males 1.54 × 10-5 1.95 × 10-3 unknown
7 35,084,096 rs10486661 Females 9.34 × 10-6 9.98 × 10-5 unknown TBX20
9 20,592,188 rs7867710 Females 6.96 × 10-4 2.97 × 10-3 intron MLLT3
9 88,679,511 rs1779308 Males 3.09 × 10-3 4.94 × 10-3 unknown
11 96,720,041 rs10501872 Females 4.03 × 10-4 1.02 × 10-3 unknown
12 20,059,354 rs10505843 Females 2.02 × 10-4 7.38 × 10-3 unknown
13 52,997,850 rs9316628 Females 2.51 × 10-3 5.22 × 10-4 unknown
13 107,573,163 rs1223978 Males 3.42 × 10-4 5.07 × 10-4 unknown
15 55,974,260 rs10518945 Females 6.19 × 10-5 6.15 × 10-4 unknown ALDH1A2
17 11,054,857 rs2024134 Males 4.75 × 10-3 6.31 × 10-5 unknown
17 53,546,007 rs181224 Males 2.15 × 10-5 2.90 × 10-3 unknown Dlc2/OR4D1/OR4D2
18 48,132,968 rs768207 Females 1.35 × 10-4 2.57 × 10-4 intron DCC
20 18,310,297 rs2328293 Females 7.74 × 10-4 4.35 × 10-3 locus C20orf12
* Femoral neck, Trochanter, Lumbar spine BMD
** Percentage of traits nominally significantly associated with the SNP at p < 0.01 in both GEE and FBAT
†Subsamples with N < 400 excluded.
‡Percentage of traits nominally significantly associated at p < 0.01 in both GEE and FBAT was 67% for all SNPs.BMC Medical Genetics 2007, 8(Suppl 1):S14 http://www.biomedcentral.com/1471-2350/8/S1/S14
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on the  HapMap website for the SNPs widely studied by
others with respect to BMD (rs4988321 and rs627174).
For the VDR  gene there was a single 100K SNP
(rs2189480) nominally significantly associated with fem-
oral neck section modulus and spine BMD; however,
there were no data available on LD between this 100K
SNP and the 3 out of 5 SNPs reported in a recent meta-
analysis of association studies for osteoporosis [29]. Two
SNPs reported in that meta-analysis (rs1544410 and
rs11568820) were not in LD with the one 100K SNP stud-
ied here. There were two 100K SNPs in the CYP19 gene
(rs10519297 and rs2008691) associated with femoral
neck-shaft angle that were in LD with at least one of the
previously reported SNPs studied with respect to bone
phenotypes (rs700518, rs4775936, rs10046, and
rs11575899). Also, there was a single 100K SNP in the
COL1A1 gene (rs2075555) that was associated with fem-
oral neck width in women and shaft width in men; how-
ever, there were no data at the HapMap website regarding
LD with the three other SNPs in this gene reported by
other osteoporosis research groups (rs1107946,
rs11327935, rs1800012).
Discussion
To our knowledge, this is the first genome-wide association
study of many of the most commonly measured osteoporosis-
related phenotypes. This unbiased approach allowed simultane-
ous exploration of multiple genetic loci rather than focusing on
a single-gene association. Using a strategy that combined
GEE and FBAT association tests within the subgroup of
BMD traits, 40 SNPs were each found to be associated
with several bone phenotypes. More than half of these
were in or near several genes, including cadherin 9 type 2
(CDH9) on 5p14, nuclear receptor subfamily 5, group A
gene (NR5A2) at 1q32, gene deleted in colorectal carci-
noma (DCC) on 18q21, and PPARG on 3p25. Some of the
genes found to be associated with one or several bone
density phenotypes have not previously been studied for
osteoporosis. Analyses stratified by sex confirmed associ-
ation of BMD phenotypes with CDH9  and  DCC  in
women. The sex specificity of our findings is fully in line
with the previous observations of both sex-specific linkage
[13,21] and sex-specific genetic association with BMD
[25,41].
Our phenotypic subgroup combining BMD and the ultra-
sound trait, BUA, demonstrated that the interleukin 1
receptor-like 1 (IL1RL1) gene on 2q12 was associated with
all bone mass traits. In contrast there was a notable
absence of pleiotropic associations between BMD and hip
geometry (femoral neck length and width, neck-shaft
angle, and shaft width). This is an important observation
in light of the current debates about the role of femoral
bone geometry in fracture prediction above and beyond
BMD, as well as a criticism of DXA-derived bone geomet-
ric traits, which are perceived as partially captured in the
BMD measurement. We have clearly shown that BMD
traits (measured at the femoral neck, trochanter, and at
the lumbar spine) share associations with SNPs in several
genes, whereas there are no such SNPs that share associa-
Table 4: Associations of bone traits with selected candidate genes for osteoporosis with a FBAT or GEE p-value < 0.05
Chrom Candidate 
Gene
Published 
SNP
Ref. 100K SNP r2*P h y s i c a l  
Position
Lowest P-
value by GEE
GEE 
Phenotype
Lowest P-value 
by FBAT
FBAT 
Phenotype
1 MTHFR rs1801133                       [38] rs1801133                       self 11,790,644 0.033 ShaftZ1rm 0.042 NSA1
[39]
[28]
6 ESR1 rs2234693                       [45] rs3866461                       0.223 152,238,835 0.014 NSAm 0.003 NeckLengf
rs1884052                       0.004 152,383,480 0.002 ShaftZ1R 0.023 NeckW1rf
rs3778099                       0.002 152,510,689 0.003 BUA 0.019 FNBMD
rs9340799                       [45]
11 LRP5 rs4988321                       [40,  46] rs4988300                       no  data 67,845,407 0.038 ShaftZ1rm 0.025 FNBMDf
rs627174                       rs4988300 no data
rs3736228                       [40,  41] rs4988300 0.030
12 VDR rs11568820                        [29] rs2189480                       0.049 46,550,095 0.011 NeckZ1rm 0.021 LSBMD
rs10735810                       [29] rs2189480 no  data
rs1544410                       [29] rs2189480 0.045
rs7975232                       [29] rs2189480 no  data
rs731236                       [29] rs2189480 no data
15 CYP19 rs700518                       [47] rs10519297                       0.902 49,328,952 0.002 NSA1 0.859 NSA1
[48] rs2008691                       0.239 49,335,602 0.003 NSA1 0.012 NSA1
rs4775936                       [49] rs10519297 0.58
rs10046                       rs10519297 0.82
rs11575899                       rs10519297 no  data
17 COL1A1 rs1107946                       [50] rs2075555                       no  data 45,629,290 0.034 NeckW1rf 0.010 ShaftWm
rs11327935                                           [51] rs2075555 no  data
rs1800012                                       [52] rs2075555 no  data
* r2 between the 100K SNP and a corresponding published SNP (column to the left)
p-values < 0.005 are shown in bold.BMC Medical Genetics 2007, 8(Suppl 1):S14 http://www.biomedcentral.com/1471-2350/8/S1/S14
Page 10 of 13
(page number not for citation purposes)
tions with both hip BMD and hip geometric traits. Despite
substantial shared genetic determinants between hip
BMD and geometric traits (preliminary unpublished
results from our group), these phenotypes are at least in
part governed by distinct gene variants. Since genes con-
tributing to variation in BMD do not always contribute to
osteoporotic fractures [42], there is a necessity to geneti-
cally dissect geometric phenotypes along with BMD to
derive a valid endophenotype of osteoporosis and to bet-
ter encircle the complex heritability of this disease [31].
When we queried the FHS 100K association results, sev-
eral SNPs in previously well-studied candidate genes for
osteoporosis were identified (FBAT or GEE p < 0.05), such
as rs1801133 in MTHFR; rs1884052 and rs3778099 in
ESR1; rs4988300 in LRP5; rs2189480 in VDR; rs2075555
in  COLIA1; rs10519297 and rs2008691 in CYP19. We
also examined SNPs in other candidate genes of interest to
our group such as SNPs in PPARG  (rs10510418 and
rs2938392) that were associated with BMD and ultra-
sound and SNPs in ANKH (rs2454873 and rs379016) that
were associated with femoral neck section modulus.
We observed limited overlap between the results of the
association and linkage analyses, which may, in part, be
attributed to a low power of the linkage analysis. The res-
olution of linkage peaks depends not only upon the
extracted information content of the genotyped markers,
but also upon the useful recombination information con-
tained in the sample (which is related to family structure
and sample size). Despite low power for detecting modest
genetic effects in linkage analyses, we identified several
loci with a substantial indication of linkage, such as LOD
scores ≥3.0 on chromosomes 15 (around 55,573,538 bp)
and 22 (around 44,039,280 bp) for bone geometry phe-
notypes. Also, LOD scores for BMD phenotypes generally
increased after restricting our sample to the members of
the Offspring Cohort only, despite potential loss of power
due to smaller sample size. This observation indirectly
supports our previous finding of refined LOD scores in
subgroups of age [21] and may be explained by the
younger age of the Offspring Cohort members. The BMD
phenotypes in that cohort might be less affected by aging-
related artifacts in DXA scans, such as osteophytes, ossifi-
cation of ligaments, and abdominal aortic calcification.
We also observed little overlap between the results of the
linkage analysis reported above and our previous studies
of the same phenotypes [23,31], which may, in part, be
attributed to low power of these linkage analyses and lim-
ited overlap between the 100K sample and the relatively
large sample of FHS pedigrees published before [23,31].
To our knowledge, this is a first genome-wide association
study of many of the most commonly measured oste-
oporosis-related phenotypes. It is distinct in many
respects. First, this is a population-based sample rather
than a study of affected families. Second, our study
included adults from two generations of the same fami-
lies. The longitudinal nature of the FHS and ongoing
recruitment of the third generation (grandchildren of the
Original Cohort) will enable us to validate the results of
this study with an even larger sample of 3 generations.
Third, results of this collaborative effort (FHS 100K SNP
study) are publicly available on the web http://
www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?id=phs000007, which makes it a unique
resource contributing to ongoing efforts of other groups.
One of the strengths of this study lies in the unbiased
approach that allowed simultaneous exploration of mul-
tiple genetic loci rather than focusing on a single-gene
association. However osteoporosis is likely to be a poly-
genic condition with a strong environmental component.
Therefore, an obvious limitation of this study is the
absence of analyses testing gene-environment and gene-
by-gene interactions [43], which is a demanding element
of study design and statistical analyses. We did not for-
mally test for associations of the SNPs with some known
environmental factors, such as smoking or estrogen
replacement therapy in women, for which FHS has well-
documented longitudinal data, because of sample size
considerations.
A second potential limitation of this study is that there
may be unmeasured factors that would affect the associa-
tion or impact on generalizability of our results. Sampling
of homogenous individuals is needed to minimize these
effects. We attempted to approach this problem in part by
stratifying our sample by gender; however, a more
involved stratification, such as younger men or postmen-
opausal women, was not performed due to sample size
restrictions. A third potential shortcoming of this study is
the limited coverage of the genome by the 100K SNP
array. These SNPs are undersampled from coding regions
(both non-synonymous and synonymous) and oversam-
pled from regions outside genes, relative to SNPs in the
overall HapMap database [44]. Current plans of the FHS
include the genotyping and analysis of over half a million
genetic variants in approximately 9,000 men and women
from three generations of the FHS. This higher density
genotyping will provide wider coverage of genomic varia-
tion and thus will clearly have advantages for GWA and
linkage studies in the future.
Fourth, at the present there is no clear-cut strategy for pri-
oritization of the regions identified by our approach to
whole genome analyses. We implemented one possible
SNP prioritization strategy based on a somewhat arbitrary
grouping of multiple phenotypes. Pleiotropy across differ-
ent (but probably related) phenotypes may be an indica-BMC Medical Genetics 2007, 8(Suppl 1):S14 http://www.biomedcentral.com/1471-2350/8/S1/S14
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tion of genes that influence more than one biological
pathway and thus may affect overall risk of osteoporosis.
Finally, we are hesitant to regard any result reported in
this paper as genome-wide significant. Although observ-
ing evidence for association at a significance level of .0001
in both the GEE and FBAT test is very encouraging, it does
not meet the standard of genome-wide significance. Not
only do we have a large number of statistical tests for each
phenotype, but we also have numerous phenotypes [30].
None of our findings should be considered true positive
results until they are replicated in independent samples
and/or functional studies are performed that provide the
mechanism of the SNP effect.
Conclusions and future directions
An unbiased genome-wide strategy to detect genetic asso-
ciations with skeletal traits provides an opportunity to
identify novel pathways for replication in other human
populations. This study is thus hypothesis-generating and
awaits replication in comparable samples. On one hand,
ample data on genetic markers and associated traits may
form the basis of new phenotype definitions, aimed at
defining phenotypic groupings that are characterized by
the sharing of genetic linkage and association. Such data
may uncover biological mechanisms not obvious at the
phenotypic level [42]. On the other hand, a composite
genetic risk score that combines the effects of multiple loci
may prove to be of more practical utility for a common
and complex chronic disease such as osteoporosis, [43]
rather than results of single-gene association studies. Iden-
tification of such a molecular profile and creation of an
array for genetic screening will be a very useful tool for
prevention and management of osteoporosis.
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